Estrella Immunopharma Inc(ESLA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:51 PM ET (Korea 10/29 05:51)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.25 | Insider Own | 60.42% | Shs Outstand | 43.0M | Perf Week | 49.4% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.01% | Shs Float | 17.2M | Perf Month | 78.59% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.08 | Inst Own | 11.02% | Short Float | 3.48% | Perf Quarter | 14.11% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -1.32% | Short Ratio | 0.34 | Perf Half Y | -44.1% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -416.74% | Short Interest | 0.60M | Perf YTD | -47.33% |
| Book/sh | -0.17 | P/C | 238.26 | EPS past 3/5Y | -27.1% -70.08% | ROE | - | 52W High | -73.91% ($3.15) | Perf Year | -66.73% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 242.37% ($0.24) | Perf 3Y | -50.5% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 24.03% | Gross Margin | - | Volatility(W/M) | 33.39% 30% | Perf 5Y | -91.73% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.2 | EPS Q/Q | 65.04% | Profit Margin | - | RSI (14) | 62.35 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.2 | Sales Q/Q | - | SMA20 | 53.6% ($0.53) | Beta | 0.95 | Target Price | $12 |
| Payout | - | Debt/Eq | - | Earnings | 2026/09/02 | SMA50 | 40.43% ($0.58) | Rel Volume | 0.28 | Prev Close | $0.93 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -17.13% ($0.99) | Avg Volume(3M) | 1.74M | Price | $0.82 |
| IPO | 2021/9/14 | Option/Short | No/Yes | Trades | 957 | Volume | 495,008 | Change | -11.86% |
🧬 A clinical-stage biotech company developing next-generation immuno-oncology therapies that significantly reduce the side effects of conventional CAR-T treatments through its proprietary 'ARTEMIS®' T-cell platform. The company is building precision immuno-therapy solutions that span hematologic cancers, solid tumors, and autoimmune diseases.
Over the past 1 year, on the lower side
74% below its 1-year high.
Traded less than usual. That is 28% of its average volume.
ESLA has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #440 of 594 in the industry
Based on market cap of $36M.
EXOZ#438 eXoZymes Inc $37M PER - 
NNVC#439 NanoViricides Inc $37M PER - ESLA#440 Estrella Immunopharma Inc $36M PER - 
ACET#441 Adicet Bio Inc $36M PER - 
EDSA#442 Edesa Biotech Inc $35M PER - 
FAQ
What kind of company is ESLA?
ESLA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ESLA?
The market cap of ESLA is approximately $36M, ranking 5,015 within its sector.
What is the 52-week high and low for ESLA?
ESLA has recorded a 52-week high of $3.15 and a low of $0.24.
